Patents by Inventor Yoshinori Moriyama
Yoshinori Moriyama has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11955259Abstract: A heat detection line includes a twisted pair wire composed of a pair of heat detecting wires being twisted together. Each heat detecting wire includes a conductor and an insulator covering a periphery of the conductor. The conductor is non-magnetic and composed of a copper alloy with a tensile strength of 900 MPa or more. A multi-core cable includes the heat detection line, a plurality of electric wires, and a sheath covering the heat detection line and the plurality of electric wires together. A melting point of the insulator of the heat detection line is lower than a melting point of an insulator of each of the plurality of electric wires.Type: GrantFiled: July 21, 2021Date of Patent: April 9, 2024Assignee: PROTERIAL, LTD.Inventors: Masashi Moriyama, Yoshinori Tsukamoto, Detian Huang
-
Patent number: 11923104Abstract: A cable includes a cable core including one or more electric wires, a shield layer covering around the cable core, and a sheath covering around the shield layer. The shield layer is composed of a braided shield including a plurality of first metal wires composed of aluminum or aluminum alloy and a plurality of second metal wires composed of copper or copper alloy. The plurality of first metal wires and the plurality of second metal wires are cross-braided.Type: GrantFiled: September 7, 2021Date of Patent: March 5, 2024Assignee: PROTERIAL, LTD.Inventors: Detian Huang, Yoshinori Tsukamoto, Masanori Kobayashi, Masashi Moriyama, Koji Fukuzato
-
Patent number: 8278032Abstract: The present invention provides a lipid membrane that contains a polypeptide consisting of the amino acid sequence of SEQ ID NO: 2, 4, 6, 8, or 22. Use of the present invention enables screening for a chemical which regulates excretion of a chemical and/or a waste. Furthermore, use of the present invention enables an arbitrary chemical to be tested for nephrotoxicity and/or hepatotoxicity.Type: GrantFiled: June 17, 2010Date of Patent: October 2, 2012Assignee: Genomembrane, Inc.Inventors: Yoshinori Moriyama, Hiroshi Omote, Masato Otsuka, Takuya Matsumoto, Miki Hiasa
-
Patent number: 8067034Abstract: Disclosed are agents for phase-adjusting or enhancing the amplitude of an endogenous melatonin secretion rhythm and for improving a circadian rhythm, as well as functional food containing such an agent, which may prevent or ameliorate various symptoms, such as sleep disorder or prolonged sleep latency. The agent contains whey as the active component.Type: GrantFiled: December 7, 2007Date of Patent: November 29, 2011Assignee: CALPIS Co., LtdInventors: Yoshinori Moriyama, Seiji Tsuboi, Akihiro Masuyama, Toshiaki Takano, Keita Ueno, Toshiyuki Kai
-
Patent number: 7951595Abstract: It is an object of the invention to isolate a transporter responsible for ATP transport and a gene encoding the transporter. It is another object of the invention to provide a method for the screening of a medicament for treating and/or regulating pain in central nerves, blood coagulation by platelet-derived ATP, or the like, the method employing such a transporter. According to the invention, a transporter responsible for ATP transport and a gene encoding the transporter were isolated. Furthermore, there is provided a method for the screening of a medicament for treating and/or regulating pain in central nerves, blood coagulation by platelet-derived ATP, or the like, the method employing such a transporter.Type: GrantFiled: March 4, 2008Date of Patent: May 31, 2011Assignee: National University Corporation Okayama UniversityInventors: Yoshinori Moriyama, Hiroshi Omote, Keisuke Sawada
-
Patent number: 7892728Abstract: The present invention provides a lipid membrane that contains a polypeptide consisting of the amino acid sequence of SEQ ID NO: 2, 4, 6, 8, or 22. Use of the present invention enables screening for a chemical which regulates excretion of a chemical and/or a waste. Furthermore, use of the present invention enables an arbitrary chemical to be tested for nephrotoxicity and/or hepatotoxicity.Type: GrantFiled: October 12, 2006Date of Patent: February 22, 2011Assignee: Genomembrane, Inc.Inventors: Yoshinori Moriyama, Hiroshi Omote, Masato Otsuka, Takuya Matsumoto, Miki Hiasa
-
Publication number: 20100279331Abstract: The present invention provides a lipid membrane that contains a polypeptide consisting of the amino acid sequence of SEQ ID NO: 2, 4, 6, 8, or 22. Use of the present invention enables screening for a chemical which regulates excretion of a chemical and/or a waste. Furthermore, use of the present invention enables an arbitrary chemical to be tested for nephrotoxicity and/or hepatotoxicity.Type: ApplicationFiled: June 17, 2010Publication date: November 4, 2010Applicant: Genomembrane, Inc.Inventors: Yoshinori Moriyama, Hiroshi Omote, Masato Otsuka, Takuya Matsumoto, Miki Hiasa
-
Patent number: 7785633Abstract: The present invention provides an agent for preventing or suppressing hepatic dysfunction which may be taken daily and continuously, has excellent safety, and is capable of effectively preventing and/or suppressing hepatic dysfunction, such as hepatocellular necrosis, and functional food, such as foods for specified health uses, for preventing or suppressing hepatic dysfunction containing this agent. The agent for preventing or suppressing hepatic dysfunction of the present invention contains whey as the active component, and the functional food for preventing or suppressing hepatic dysfunction contains the agent for preventing or suppressing hepatic dysfunction.Type: GrantFiled: December 7, 2007Date of Patent: August 31, 2010Assignee: Calpis Co., LtdInventors: Yoshinori Moriyama, Seiji Tsuboi, Akihiro Masuyama, Toshiaki Takano, Teppei Nakamura
-
Publication number: 20100167411Abstract: It is an object of the invention to isolate a transporter responsible for ATP transport and a gene encoding the transporter. It is another object of the invention to provide a method for the screening of a medicament for treating and/or regulating pain in central nerves, blood coagulation by platelet-derived ATP, or the like, the method employing such a transporter. According to the invention, a transporter responsible for ATP transport and a gene encoding the transporter were isolated. Furthermore, there is provided a method for the screening of a medicament for treating and/or regulating pain in central nerves, blood coagulation by platelet-derived ATP, or the like, the method employing such a transporter.Type: ApplicationFiled: March 4, 2008Publication date: July 1, 2010Applicant: NATIONAL UNIVERSITY CORPORATION OKAYAMA UNIVERSITYInventors: Yoshinori Moriyama, Hiroshi Omote, Keisuke Sawada
-
Publication number: 20090042219Abstract: The present invention provides a lipid membrane that contains a polypeptide consisting of the amino acid sequence of SEQ ID NO: 2, 4, 6, 8, or 22. Use of the present invention enables screening for a chemical which regulates excretion of a chemical and/or a waste. Furthermore, use of the present invention enables an arbitrary chemical to be tested for nephrotoxicity and/or hepatotoxicity.Type: ApplicationFiled: October 12, 2006Publication date: February 12, 2009Applicant: GENOMEMBRANE, INC.Inventors: Yoshinori Moriyama, Hiroshi Omote, Masato Otsuka, Takuya Matsumoto, Miki Hiasa
-
Publication number: 20080268065Abstract: The invention provides agents for phase-adjusting or enhancing the amplitude of an endogenous melatonin secretion rhythm and for improving a circadian rhythm, which may be taken daily and continuously, have excellent safety, and may effectively prevent or ameliorate disorders of an endogenous melatonin secretion rhythm or of a circadian rhythm without administration of exogenous melatonin, as well as functional food containing such an agent, which may prevent or ameliorate various symptoms, such as sleep disorder or prolonged sleep latency. The agent for phase-adjusting or enhancing the amplitude of an endogenous melatonin secretion rhythm according to the invention contains whey as the active component. The functional food for improving an endogenous melatonin secretion rhythm according to the invention contains the agent for phase-adjusting or enhancing the amplitude of an endogenous melatonin secretion rhythm.Type: ApplicationFiled: December 7, 2007Publication date: October 30, 2008Inventors: Yoshinori MORIYAMA, Seiji Tsuboi, Akihiro Masuyama, Toshiaki Takano, Keita Ueno, Toshiyuki Kai
-
Publication number: 20080085321Abstract: The present invention provides an agent for preventing or suppressing hepatic dysfunction which may be taken daily and continuously, has excellent safety, and is capable of effectively preventing and/or suppressing hepatic dysfunction, such as hepatocellular necrosis, and functional food, such as foods for specified health uses, for preventing or suppressing hepatic dysfunction containing this agent. The agent for preventing or suppressing hepatic dysfunction of the present invention contains whey as the active component, and the functional food for preventing or suppressing hepatic dysfunction contains the agent for preventing or suppressing hepatic dysfunction.Type: ApplicationFiled: December 7, 2007Publication date: April 10, 2008Inventors: Yoshinori MORIYAMA, Seiji Tsuboi, Akihiro Masuyama, Toshiaki Takano, Teppei Nakamura
-
Publication number: 20070224285Abstract: The present invention provides an agent for preventing or suppressing hepatic dysfunction which may be taken daily and continuously, has excellent safety, and is capable of effectively preventing and/or suppressing hepatic dysfunction, such as hepatocellular necrosis, and functional food, such as foods for specified health uses, for preventing or suppressing hepatic dysfunction containing this agent. The agent for preventing or suppressing hepatic dysfunction of the present invention contains whey as the active component, and the functional food for preventing or suppressing hepatic dysfunction contains the agent for preventing or suppressing hepatic dysfunction.Type: ApplicationFiled: March 31, 2005Publication date: September 27, 2007Applicant: CALPIS CO., LTDInventors: Yoshinori Moriyama, Seiji Tsuboi, Akihiro Masuyama, Toshiaki Takano, Teppei Nakamura
-
Publication number: 20070207134Abstract: The invention provides agents for phase-adjusting or enhancing the amplitude of an endogenous melatonin secretion rhythm and for improving a circadian rhythm, which may be taken daily and continuously, have excellent safety, and may effectively prevent or ameliorate disorders of an endogenous melatonin secretion rhythm or of a circadian rhythm without administration of exogenous melatonin, as well as functional food containing such an agent, which may prevent or ameliorate various symptoms, such as sleep disorder or prolonged sleep latency. The agent for phase-adjusting or enhancing the amplitude of an endogenous melatonin secretion rhythm according to the invention contains whey as the active component. The functional food for improving an endogenous melatonin secretion rhythm according to the invention contains the agent for phase-adjusting or enhancing the amplitude of an endogenous melatonin secretion rhythm.Type: ApplicationFiled: March 31, 2005Publication date: September 6, 2007Inventors: Yoshinori Moriyama, Seiji Tsuboi, Akihiro Masuyama, Toshiaki Takano, Keita Ueno, Toshiyuki Kai